Health
Immune-Modulating Therapy Gets FDA Nod for Frontotemporal Dementia Trials, Raising Hopes for Disease-Modifying Approach
FDA clears Coya Therapeutics' COYA 302 for FTD trials, targeting immune regulation in neurodegeneration. No approved treatments exist for this progressive dementia.